Nonketotic Hyperglycinemia

Watchlist

(log in to enable)

Retrieved

2021-01-18

Source

Gene_reviews

Trials

—

Genes

GLDC, AMT, GCSH, SLC6A9, GLRX5, IRF6, GLYCTK, OCA2, LIAS, GCLC, UGCG, BOLA3, LIPT1, B3GAT1, PTPRC, SURF1, CD19, MAPK8, MAPK3, MGAT1, PSS

Drugs

Sodium benzoate

Interested in hearing about new therapies?

Summary

Clinical characteristics.

Nonketotic hyperglycinemia (NKH) is the inborn error of glycine metabolism defined by deficient activity of the glycine cleavage enzyme system (GCS), which results in accumulation of large quantities of glycine in all body tissues including the brain. Based on ultimate outcome NKH is categorized into severe NKH (no developmental progress and intractable epilepsy) and attenuated NKH (variable developmental progress and treatable or no epilepsy). The majority of children with NKH have onset in the neonatal period manifest as progressive lethargy evolving into profound coma and marked hypotonia; 85% have severe NKH and 15% attenuated NKH. Those with onset between two weeks and three months typically present with hypotonia; 50% have severe NKH and 50% attenuated NKH. Those with onset after age three months have attenuated NKH. Severe versus attenuated NKH is consistent within families, but the degree of developmental progress in those with attenuated NKH can vary.

Diagnosis/testing.

The diagnosis of NKH is established in a proband with elevated glycine in plasma and CSF, a compatible pattern on brain imaging, and either biallelic pathogenic variants in one of the genes encoding the protein subunits of the GCS identified on molecular genetic testing or deficient activity of the GCS (without deficiency of cofactors such as enzyme-bound lipoate or pyridoxal-phosphate).

Management.

Treatment of manifestations:

Severe NKH. No treatment is effective in changing the natural history of developmental delays, spasticity, and intractable epilepsy, but treatment with benzoate to lower glycine improves attentiveness and facilitates seizure management.
Attenuated NKH. Current treatment is reduction of plasma concentration of glycine by administration of sodium benzoate and blockade of overstimulated NMDA receptors.

Surveillance: In the first years of life: routine developmental assessments and neurologic evaluations. Monitoring for scoliosis and hip dysplasia in severely affected patients; gastrointestinal problems; and pulmonary function particularly in children who develop recurrent respiratory infections.

Agents/circumstances to avoid: Valproate, which raises blood and CSF glycine concentrations and may increase seizure frequency; vigabatrin, which has resulted in rapid loss of function when used to treat seizures, particularly in those with attenuated NKH who have West syndrome.

Genetic counseling.

NKH is inherited in an autosomal recessive manner. The parents of an affected individual are typically heterozygotes (i.e., carriers of one NKH-related pathogenic variant); however, de novo pathogenic variants occur in approximately 1% of individuals with NKH. If both parents are heterozygous for one pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the pathogenic variants in an NKH-related gene have been identified in an affected family member, carrier testing for at-risk relatives, prenatal diagnosis for a pregnancy at increased risk, and preimplantation genetic diagnosis are possible.

Diagnosis

Suggestive Findings

Nonketotic hyperglycinemia (NKH) due to biallelic pathogenic variants in one of the two genes (GLDC and AMT) known to encode the components of the glycine cleavage enzyme system or possibly in a third gene (GCSH) should be suspected in individuals with the following clinical, laboratory, and neuroimaging findings.

Clinical findings

Neonates with hypotonia, lethargy, coma, apnea, seizures with or without a burst suppression pattern on EEG
Infants with lethargy, hypotonia, seizures, poor feeding, developmental delays
Children with developmental delays (with expressive language more impaired than receptive language), hyperactivity with or without choreatic movements, particularly with episodic worsening of manifestations
Individuals with isolated elevated levels of plasma glycine, particularly when associated with hyperactivity, developmental delays, and/or seizures, or any of the other above manifestations

Laboratory findings

The combination of isolated elevation of levels of glycine in plasma and CSF (obtained simultaneously) by quantitative amino acid analysis (Table 1) and an abnormal CSF-to-plasma glycine ratio makes the likelihood of NKH high and requires confirmatory testing (see Establishing the Diagnosis).
Note: (1) Accurate measurement of CSF glycine requires that the CSF be completely free of contamination by blood or serum (which is not visible to the eye), as evidenced by a normal RBC (red blood cell) count and protein concentration. The presence of blood or elevated protein in the CSF invalidates the results. (2) The elevation of CSF glycine is more important than the ratio, which is only a secondary measure. (3) In CSF, the serine concentration can be low, but the threonine concentration should not be elevated. (4) The elevation of glycine levels in CSF in NKH is usually higher than that observed in disorders affecting the cofactors of the glycine cleavage enzyme system (lipoate, pyridoxal-phosphate) and overlaps with attenuated NKH, but exceptions exist [Mills et al 2010, Baker et al 2014]. (5) Documentation of a normal level of pyridoxal-phosphate in the CSF helps to exclude disorders of pyridoxal-phosphate metabolism, which can similarly raise CSF glycine levels. Further testing is needed to distinguish between the various glycine encephalopathies (see Differential Diagnosis).
Urine organic acid profile is expected to be normal. Small elevations of multiple acylglycine esters can occasionally be noticed.

Table 1.

CSF and Plasma Glycine Concentration (µmol/L) in Nonketotic Hyperglycinemia (NKH)

	NKH Phenotype		Normal Control
	Severe NKH ¹	Attenuated NKH ¹	Normal Control
CSF glycine concentration	228 (40-510) ²	99 (41-230)	<20 µmol/L ³
Plasma glycine concentration	1133 (342-2363)	822 (342-1590)	125-450 ^3, 4
CSF/plasma glycine ratio ⁵	0.22 (0.09-0.45)	0.13 (0.04-0.22)	≤0.02

: From Steiner et al [1996], Applegarth & Toone [2001], Jaeken et al [2002]
1.: Average (range) [Swanson et al 2015]
2.: The author knows of very rare cases of intermittently normal CSF glycine.
3.: Normal values vary with age. Both CSF and plasma glycine concentrations are higher in the neonatal period and decrease rapidly in the first months of life (e.g., at age >1 year, normal values for CSF glycine concentration are <12 µmol/L and for plasma glycine concentration are <350 µmol/L).
4.: Applegarth et al [1979]
5.: Samples must be obtained simultaneously.

Brain MRI

The most consistent abnormalities are noted on diffusion-weighted imaging in the first three months of life, when the vast majority of individuals with NKH present clinically. All infants with NKH have diffusion restriction in the posterior limb of the internal capsule, anterior brain stem, posterior tegmental tracts, and cerebellum (see Figure 1) [Stence et al 2019].
While the diffusion restriction in the infratentorial regions recedes after age three months, it often extends upwards to the motor cortex and a generalized diffusion restriction of the supratentorial white matter can be recognized between ages three and 14 months.
Other
- The corpus callosum can be thin and shortened but is not absent.
- A small group of infants develop hydrocephalus, often with an enlarged retrocerebellar cystic region.
- Atrophy is present in older individuals with severe NKH, but often not in individuals with attenuated NKH.

Figure 1.

Diffusion-weighted images of a neonate with classic NKH showing diffusion restriction: A. At the level of the posterior limb of the internal capsule; and

Brain magnetic resonance spectroscopy (MRS). On short echo time (TE = 35 msec) MRS, the glycine signal at 3.55 ppm coincides with myoinositol; however, at intermediate echo time (TE = 135 msec), glycine is recognized at 3.6 ppm without overlap. In most patients with severe NKH a clear glycine peak is present, whereas in attenuated NKH the glycine peak is lower and sometimes difficult to detect [Heindel et al 1993, Gabis et al 2001, Stence et al 2019].

Establishing the Diagnosis

The diagnosis of NKH is established in a proband with elevated glycine in plasma and CSF (Table 1), a compatible pattern on brain imaging, and either biallelic pathogenic variants in one of the genes encoding the protein subunits of the GCS identified on molecular genetic testing (Table 2) or deficient activity of the GCS (without deficiency of cofactors such as enzyme-bound lipoate or pyridoxal-phosphate). Today, confirmatory testing is primarily by molecular genetic testing; enzymatic testing is used only in select cases.

Molecular genetic testing. GLDC (encoding the GCS P-protein component) and AMT (encoding the GCS T-protein component) are the two genes in which biallelic pathogenic variants are known to cause NKH. Biallelic pathogenic variants in GCSH (encoding the GCS H-protein component) have been proposed as a cause of NKH in two individuals [C Acquaviva, P Rodríguez-Pomb, personal communications]; however, this remains unconfirmed.

Currently the most common testing strategy is to perform concurrent testing of all three genes (GLDC, AMT, and GCSH) by use of a multigene panel that includes these three genes and other genes of interest (see Differential Diagnosis). For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see Table 1).

The following considerations regarding multigene panels are offered by GeneReviews: Such a multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

Table 2.

Molecular Genetic Testing Used in Nonketotic Hyperglycinemia (NKH)

Gene ^1, 2	Proportion of NKH Attributed to Pathogenic Variants in This Gene	Proportion of Pathogenic Variants ^3, 4 Detectable by Method
Gene ^1, 2		Sequence analysis ⁵	Gene-targeted deletion/duplication analysis ⁶
AMT	20% ⁷	>99%	Unknown ⁶
GLDC	80%	80%	20% ⁷
GCSH		See footnote 8

1.: Genes are listed in alphabetic order.
2.: See Table A. Genes and Databases for chromosome locus and protein.
3.: See Molecular Genetics for information on allelic variants detected in this gene.
4.: See Table 5 for common AMT and GLDC variants for which laboratories may offer targeted analysis.
5.: Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
6.: Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
6.: Large deletions or duplications of AMT have not been reported, but would be expected to be pathogenic due to the loss-of-function disease mechanism.
7.: Coughlin et al [2017]
8.: Although two individuals homozygous for a GCSH pathogenic variant were reported (as an abstract at a meeting), to date no proof of pathogenicity has been provided. No other instances of NKH caused by GCSH deficiency have been identified. The H-protein has a known role in in lipoate synthesis and could potentially affect lipoate metabolism [Mayr et al 2014]. One individual was identified with deficient H-protein enzyme activity in 1981, but this likely represented a deficiency of lipoylation. No pathogenic variant was identified in the comprehensive analysis of pathogenic variants in NKH [Kure et al 2006a, Coughlin et al 2017].

Analysis of the activity of the glycine cleavage enzyme system (GCS), the major degradative pathway for glycine (see Figure 2), requires analysis of a liver biopsy, usually obtained by surgical endoscopy as a wedge biopsy or as soon as possible at autopsy. Because the enzyme is labile, rapid processing and deep freezing are essential for proper enzyme assay.

Figure 2.

Metabolism of glycine by glycine cleavage enzyme. Glycine enters the four-protein enzyme complex at the lower left, where it is decarboxylated by the P-protein (also known as glycine decarboxylase). A defect of the P-, H-, or T-proteins of this complex (more...)

The vast majority of individuals with NKH have no detectable GCS activity.
Individuals with a defect in the T-protein component (encoded by AMT) tend to have GCS activity up to 25% of normal values. Conversely, 50% of individuals with residual GCS activity in liver have AMT pathogenic variants [Toone et al 2003]. Individuals with a defect in the P-protein component (encoded by GLDC) do not tend to have residual GCS activity [Toone et al 2000] except for those who are mildly affected.
Up to 5% of persons with deficient GCS activity do not have pathogenic variants in any NKH-related gene. These individuals could have pathogenic variants in genes encoding proteins involved in either GCS cofactors (lipoate and pyridoxal-phosphate) or glycine transport (see Table 3, Differential Diagnosis).

Note: Although enzymatic confirmation of NKH using Epstein-Barr virus cultured lymphoblasts from peripheral blood samples was reported in six individuals with P-protein defects, others have obtained overlapping GCS activity in both controls and individuals with NKH, making this method unreliable [Applegarth et al 2000b].

Other testing (used in some locations):

Glycine exchange reaction, which measures the combined activity of the P- and H-protein without the need for T-protein activity, can assist in identifying the specific subunit involved.
¹³C-glycine breath test shows decreased ¹³C-CO₂ exhalation in patients with NKH [Kure et al 2006b].

Clinical Characteristics

Clinical Description

NKH is categorized into severe NKH and attenuated NKH based on ultimate outcome [Swanson et al 2015]:

Severe NKH. Children make no developmental progress and have intractable epilepsy.
Attenuated NKH. Children make variable developmental progress and have treatable or no epilepsy. Attenuated NKH is further divided into:
- Attenuated poor. Children have a developmental quotient (DQ) of <20 and all have epilepsy.
- Attenuated intermediate. Children have a DQ of 20 to 50 and easily treatable epilepsy or no epilepsy.
- Attenuated good. Children have a DQ >50 and do not have epilepsy.

The majority of children with NKH present in the neonatal period or in early infancy, with only the mildest cases presenting in late infancy or childhood. Outcomes by age of onset are as follows:

Neonatal onset. 85% have severe NKH and 15% have attenuated NKH.
Infantile onset (i.e., >2 weeks). 50% have severe NKH and 50% have attenuated NKH [Hennermann et al 2012, Swanson et al 2015].
Onset age >3 months. All had attenuated NKH.

Presentation

Neonatal (first hours to days of life) with progressive lethargy evolving into profound coma and marked hypotonia. In 80% of infants ventilatory drive slows, leading to prolonged apnea and often death if not supported by intubation and ventilation; in contrast, 20% of infants maintain spontaneous ventilation. The vast majority of infants regain spontaneous respiration within the first three weeks of life, and some show some spontaneous improvement in alertness in the first month of life, often with oral bottle drinking.

Myoclonic jerks and hiccups are often a sign of epilepsy. A history of prenatal hiccups is frequently present.

The initial EEG often shows a burst suppression pattern.

Infantile (age >2 weeks to 3 months). While these infants do not have lethargy and coma in the first days of life, they often have a history of hypotonia from early on. They present with developmental delay and infantile-onset seizures that can be mild or increasingly difficult to treat.

Late (age >3 months) is rare, is always associated with the attenuated form, and involves developmental delays and possible mild seizures.

Outcome

Severe NKH. Many infants never make any developmental gains, but some regain some skills such as spontaneous bottle feeding, looking, and smiling, particularly when treated with benzoate (see Management). At most, affected children learn to smile and roll from side to back or side to front (i.e., developmental age 6 weeks to 3 months). At about age three to four months they begin to lose skills such as bottle feeding. They do not learn to sit or grasp; they have limited interaction with their environment.

Before age six months children with severe NKH begin to develop progressive spasticity (hyperreflexia, distal hypertonicity, and positive Babinski signs) and cortical blindness (often with poor fixation and sometimes with roving eye movements). Most have swallowing dysfunction requiring tube feeding.

Increasingly difficult-to-treat seizures develop in the first year, usually requiring multiple anticonvulsants with incomplete seizure control. The EEG pattern can evolve into hypsarrhythmia and/or multifocal spikes.

Many develop scoliosis or hip dislocation often requiring surgical intervention (if indicated in the overall condition) in childhood or adolescence [Ramirez et al 2012].

Occasionally children with severe NKH have cleft palate or clubfeet [Hennermann et al 2012]. Some develop secondary microcephaly.

Attenuated NKH (with outcomes ranging from poor to intermediate to good). In general, children in this category make variable developmental progress. They can learn to walk, reach and grasp, use sign language, and interact with caregivers and attend special education classes. They have little spasticity.

They may develop a seizure disorder, which is often relatively easy to treat with either benzoate or dextromethorphan alone or with the addition of a single anticonvulsant [Van Hove et al 2005] (see Management).

Hyperactivity is common, often severe, and poorly responsive to interventions [Wiltshire et al 2000, Hennermann 2006].

Many have choreic movements, a good prognostic sign [Hennermann et al 2012].

They can have intermittent episodes of severe lethargy, often triggered by fever and infection (sometimes reported in the past as a "mild episodic form").

An adult experienced acute decompensation while on valproate (which is contraindicated) [Hall & Ringel 2004] (see Management).

Poor outcome (DQ <20). Individuals in this category have manifestations intermediate between attenuated and severe NKH. Developmentally, they learn to grasp objects, usually are able to sit, and have limited interaction with some signs. Spasticity – which is less than that observed in severe NKH – is nonetheless noticeably present. Although epilepsy is usually controlled with one or two anticonvulsants, hypsarrhythmia that is not controlled with anticonvulsants portends a poor outcome.
Intermediate outcome (DQ 20-50). Individuals in this category learn to walk and communicate with some speech but mostly sign language. They can grasp items purposefully and eat independently. They attend special education classes in school. Most have choreatic movements, and pronounced hyperactivity, often in bursts.
Good outcome (DQ >50). Individuals in this category make substantial developmental progress and do not have epilepsy. Half of the individuals in this category present after age three months, with a few presenting after age one year. They sometimes can attend normal class in school. They have attention deficit and hyperactivity disorder (ADHD).
They can have episodes of severe lethargy with infections [Brunel-Guitton et al 2011]. The recognition of the episodes of lethargy led to the description of the "mild episodic form," reported in four children with mild intellectual disability and episodes of chorea, agitated delirium, and vertical gaze palsy associated with febrile illness [Steiner et al 1996].
Individuals homozygous for p.Ala802Val (which is associated with substantial residual GCS activity) who received early and aggressive treatment in the first two years of life had normal intelligence [Korman et al 2004] (see Management).

Other findings include the following [Authors, unpublished observations]:

A number of patients have had delayed gastric emptying and poor gastrointestinal motility, leading to very severe problems including dependency on total parenteral nutrition (TPN) in a few.
A few patients had sudden severe electrolyte disturbances including profound hypokalemia causing sudden cardiac arrest. This occurrence was rare (<1%) and did not recur.
A few patients have reported dysuria with difficulty emptying the bladder. It is unclear if this is a side effect of dextromethorphan or a manifestation of the disorder.
In infants with severe NKH, a retrocerebellar cyst with subsequent development of hydrocephalus occurred in 3% of cases [Van Hove et al 2000], requiring ventriculoperitoneal shunt placement.
Patients can have recurrent and long episodes of unexplained severe crying.

Note: Some atypical manifestations historically reported as NKH (e.g., cardiomyopathy or with optic atrophy) are consistent with features of variant NKH (lipoate, iron-sulfur cluster defects) (see Differential Diagnosis), and not with classic NKH caused by deficient GCS activity due to biallelic pathogenic variants in AMT or GLDC.

Intrafamilial Variability

The phenotype of severe versus attenuated NKH is consistent within families, but the subcategory of attenuated NKH and degree of developmental progress can vary.

A retrospective study showed a consistent phenotype within seven families with two or more affected children [Hoover-Fong et al 2004]. The familial concordance for outcome has been observed in several additional families.

In sibs with significant variability in developmental outcome for attenuated NKH, aggressive treatment in the first two years of life with sodium benzoate and N-methyl D-aspartate (NMDA) receptor site antagonists was associated with improved developmental outcome [Korman et al 2004, Bjoraker et al 2016] (see Management).

Prognostic Predictors

Age at presentation. Patients presenting later have attenuated disease; however, early presentation is not sufficiently predictive as 15% of patients who present as neonates have attenuated disease.

Biochemically, plasma glycine alone does not predict developmental outcome. CSF glycine elevated >230 μmol/L predicts severe outcome; a CSF:plasma glycine ratio of <0.08 predicts attenuated outcome [Swanson et al 2015].

Radiologically, the presence of hydrocephalus predicts severe NKH; the presence of a very thin and shortened corpus callosum also predicts severe NKH [Van Hove et al 2000, Stence et al 2019].

The pattern of diffusion restriction on brain MRI is not predictive of phenotype [Stence et al 2019].

Clinically, the development of clear pyramidal tract signs before age six months predicts severe NKH, whereas the presence of choreatic movements predicts attenuated NKH [Hennermann et al 2012]. Attenuated NKH with a poor outcome can have signs intermediate between severe and attenuated outcome and early on can be difficult to distinguish clinically. Cleft palate and clubfeet when present predict severe outcome.

EEG. Persistent burst suppression pattern tends to be associated with severe outcome.

MRS. The glycine/creatine ratio is higher in severe than in attenuated NKH [Stence et al 2019].

Genotype. For genotypes that predict prognosis, see Genotype-Phenotype Correlations.

Genotype-Phenotype Correlations

There are no clinical differences between individuals with biallelic pathogenic variants in GLDC and those with pathogenic variants in AMT.

Glycine cleavage enzyme system (GCS) activity predicts severe versus attenuated outcome in NKH (see Clinical Description) [Swanson et al 2015] as follows:

Biallelic pathogenic variants associated with lack of residual GCS activity, such as exon copy number variants, frameshift variants, nonsense variants, and consensus splice site variants (-1,2 or +1,2), have no residual activity except the following GLDC variants: c.2203-2A>G and c.2999delG (p.Cys1000LeufsTer31), a very late frameshift.
Biallelic pathogenic variants with preserved residual GCS activity predict attenuated NKH, with the majority having attenuated good outcome.
The presence of one variant with preserved residual GCS activity usually results in attenuated NKH, and on occasion results in severe NKH. In patients with attenuated NKH, outcome ranges from attenuated poor to intermediate, with a few good.
Note: The amount of residual activity detected in expression studies sufficient for attenuated outcome is as low as 1%.
The residual function of a missense variant may be difficult to assess for the purpose of predicting genotype-phenotype correlation:
- Thus far, the expression of 47 missense GLDC variants has been reported [Swanson et al 2015, Bravo-Alonso et al 2017]. Commonly recurring variants are listed in Table 5.
- The expression of AMT variants has not yet been reported, but clinical studies implicate the very common pathogenic variant p.Arg320His as severe.

Nomenclature

Collectively, neurologic disorders caused by disturbance of glycine metabolism and transport are termed "glycine encephalopathy." See Differential Diagnosis for details about other inherited disorders causing glycine encephalopathy.

Note: The term "atypical NKH" is no longer used as it combined cases of attenuated NKH and variant NKH (see Table 3) and therefore was inconsistent and nonspecific. Many individuals described in the past as having atypical NKH (e.g., NKH with optic atrophy and progressive spasticity, NKH with cardiomyopathy, or NKH with pulmonary hypertension) are now known to have – or likely had – lipoate deficiency disorders.

Prevalence

The birth incidence of NKH has been estimated at 1:55,000 newborns in Finland (1:12,000 in an area of Northern Finland) and 1:63,000 in British Columbia, Canada [Applegarth et al 2000a]. The calculated carrier frequency is approximately 1:125 in the population of British Columbia, Canada (predominantly a population of northern European origin at the time of data collection for disease incidence). Using publicly available population genotypes, the birth estimate of NKH worldwide was estimated at 1:76,000 [Coughlin et al 2017]. An increased incidence is expected in populations with founder variants (see Table 5).

NKH may be underdiagnosed for several reasons:

Attenuated NHK and severe NKH without apnea are clinically underappreciated (e.g., identification on exome sequencing in cases of autism [Yu et al 2013]).
Analysis of CSF amino acids to detect elevated CSF glycine in infants with neonatal/infantile epilepsy, a primary trigger for suspicion of NKH, is not consistently obtained; furthermore, in NKH plasma glycine levels can be normal, and elevated levels are not specific for NKH.
Multigene panels for neonatal/infantile epilepsy often do not include GLDC and AMT unless specifically requested.

Differential Diagnosis

Inherited disorders in the differential diagnosis of nonketotic hyperglycinemia (NKH) caused by deficient activity of the glycine cleavage enzyme system (GCS) are outlined in Table 3.

Table 3.

Inherited Disorders in the Differential Diagnosis of NKH

	Disorder	Gene(s)	MOI	Clinical Findings	Laboratory Findings
GCS cofactor deficiency ¹	Lipoate deficiency ²	LIAS LIPT2 BOLA3 GLRX5 IBA57 NFU1	AR	DD, seizures, spasticity, ataxia, optic atrophy, pulmonary hypertension, cardiomyopathy	Elevated plasma & CSF glycine levels Deficient GCS activity Deficient pyruvate dehydrogenase enzyme activity
	Pyridoxine-dependent epilepsy ³	ALDH7A1	AR	Neonatal epileptic encephalopathy responsive to pyridoxine treatment	Elevated plasma & CSF glycine levels Deficient GCS activity
	PNPO deficiency ³ (OMIM 610090)	PNPO	AR	Severe neonatal seizures & coma; ± apnea; seizures respond to pyridoxal-5'-phosphate treatment ⁴	Elevated CSF glycine levels Low CSF pyridoxal-phosphate
	PLPBP deficiency ³ (OMIM 617290)	PLPBP	AR	Presentation similar to PNPO deficiency	Elevated CSF glycine levels Low CSF pyridoxal-phosphate
Abnormal regulation of GCS	cblX (cobalamin X) ⁵ (see Disorders of Intracellular Cobalamin Metabolism)	HCFC1	XL	Males: neonatal seizures	Elevated plasma & CSF glycine levels Combined methylmalonic aciduria & hyperhomocysteinemia
Glycine transport defect	GLYT1 encephalopathy	SLC6A9	AR	Neonatal encephalopathy, impaired consciousness, often poor respiratory drive, death usually < age 1 yr	Elevated CSF glycine (range: 21-33 μmol/L) Normal plasma glycine & elevated CSF:plasma glycine ratio
Inhibition of GCS activity	Organic acidurias ⁶ (e.g., MMA, PA, IVA)	Multiple genes (e.g., PCCA, PCCB, IVD, MMUT [MUT])	Typically AR	Neonatal encephalopathy, metabolic acidosis, hyperammonemia, ketones	Elevated plasma & CSF glycine levels but normal CSF:plasma glycine ratio Abnormal urine organic acids (ketotic hyperglycinemia)

: AR = autosomal recessive; CSF = cerebrospinal fluid; DD = developmental delay; GCS = glycine cleavage enzyme system; IVA = isovaleric acidemia; MMA = methylmalonic aciduria; MOI = mode of inheritance; NKH = nonketotic hyperglycinemia; PA = propionic acidemia; PLPBP = pyridoxal phosphate binding protein; PNPO = pyridoxamine 5'-phosphate oxidase; XL = X-linked
1.: "Variant NKH" refers to glycine encephalopathy with elevated glycine levels and deficient GCS activity without GLDC or AMT pathogenic variants, most commonly due to deficiencies in the metabolism